Skip to main content
. 2021 May 30;4(3):634–645. doi: 10.20517/cdr.2021.27

Figure 2.

Figure 2

FDA-approved proteasome inhibitors. Bortezomib and ixazomib contain a boronic acid pharmacophore, while a tetrapeptide carfilzomib has an epoxyketone pharmacophore.